Abstract: The present invention provides a method of inhibiting the activation of the NF.kappa.B transcription factor in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin. Also provided is a method of inhibiting the nuclear translocation of the p65 subunit of the NF.kappa.B transcription factor in a cell or in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

Abstract: This invention relates to the use of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof for the treatment of dementia.

Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.

Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.

Abstract: The present invention provides a novel gene encoding a cationic amino acid transporter protein. The present invention also provides antibodies specific for the cationic amino acid transporter protein. Further, the present invention provides methods of treating a disease characterized by undesirable levels of nitric oxide and methods of inhibiting cationic amino acid transport.

Abstract: The present invention provides a method of preparing apoenzyme of a riboflavin-dependent enzyme, comprising the steps of: growing COS-7 cells in a riboflavin-free medium; introducing a cDNA encoding a riboflavin-dependent enzyme; and expressing said cDNA. Also provided is a method of screening for an inhibitor of a flavin dependent enzyme, comprising the steps of;contracting a potential inhibitor of a flavin dependent enzyme with the cell line of claim 7 in the presence of riboflavin, FMN or Fad; and measuring the enzymatic activity of the flavin dependent enzyme.

Abstract: A method for determining a flow rate of a substance or a thermo-contrast agent in an object including a surface and an upstream region, and the method comprising the steps of (a) providing the upstream region with a thermo-contrast agent; (b) obtaining successive temperature readings of at least a part of the surface of the object; (c) generating a temperature response curve from the temperature readings; (d) extracting a parameter from the temperature response curve; and (e) determining the flow rate from the parameter.

Abstract: The present invention provides a method of treating an individual with primary adrenal insufficiency, comprising the step of administering an effective amount of dehydroepiandrosterone to said individual. Also provided is a method of treating an individual with adrenal failure secondary to dysfunctions of the hypothalamus and/or pituitary gland, comprising the step of administering an effective amount of dehydroepiandrosterone to said individual and a method of treating an individual with adrenal insufficiency due to acquired human immunodeficiency syndrome (AIDS), comprising the step of administering an effective amount of deyhydroepiandrosterone to said individual.

Abstract: The present invention provides an isolated and purified protein that associates with the cytoplasmic domain of the p60 form of the tumor necrosis factor receptor, having a molecular weight of about 52-55 kDa on SDS-PAGE, is a phosphoprotein, and does not bind to the p80 form of the tumor necrosis factor receptor. Also provided is an isolated and purified protein kinase that binds to the cytoplasmic domain of the p60 form of the tumor necrosis factor receptor, said kinase phosphorylates the p60 form of the tumor necrosis factor receptor. Also provided are various methods of manipulating this tumor necrosis factor receptor-associated protein and kinase in order to reduce various biological effects of tumor necrosis factor.

Abstract: The present invention provides a method of screening individuals at risk for developing diseases caused by trinucleotide repeat sequence instability. Specifically, the present invention is drawn to screening individuals at risk for developing autosomal dominant spinocerebellar ataxia type 6 by determining the length of a CAG trinucleotide repeat in the .alpha..sub.1A calcium channel gene of the individual. In addition, there is provided a method of identifying genes which are disease-causing due to trinucleotide repeat sequence instability by large scale genotyping.

Abstract: The present invention provides a method to design compounds that mimic the effects of Pbx in stabilizing STF-1 binding. Using well known DNA binding assays, a person having ordinary skill in this art would be able to screen compounds to determine drugs effective in promoting STF-1 binding to DNA. In this way, one will be able to discover new compounds useful in stimulating somatostatin and insulin production.

Abstract: The present invention provides a composition of matter for the treatment of non-melanoma cancers, wherein said composition comprises a platinum anti-neoplastic compound and tamoxifen, wherein said platinum anti-neoplastic compound and tamoxifen exert a synergistic anti-tumor effect on said non-melanoma cancer. Also provided are various methods of treating non-melanoma cancers and methods of preventing or overcoming resistance to platinum-containing anti-neoplastic compounds.

Abstract: The present invention provides an isolated and purified protein that associates with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor, having a molecular weight of 59 kDa on SDS-PAGE, is a phosphoprotein, and does not bind to the p60 form of the tumor necrosis factor receptor. Also provided is an isolated and purified protein kinase that associates with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor, said kinase phosphorylates both the p80 and p60 forms of the tumor necrosis factor receptor and phosphorylates a 59 kDa molecular weight protein associated with the cytoplasmic domain of the p80 form of the tumor necrosis factor receptor. Also provided are various methods of reducing the biological effects of tumor necrosis factor.

Abstract: An eye imaging system having a portable image capture unit having a circular light guide positioned adjacent to and behind a corneal contact lens for controlling directing light over a wide field to the retina of an eye and provide more light towards the center of the eye.

Abstract: The present invention provides a novel isolated and purified protein that is produced by Aedes albopictus L4.4 cells, having a molecular weight of 55 kDa of SDS-PAGE, is associated with lysosomal membranes and induces an anti-viral state. This anti-viral state is characterized by a total block of virus RNA synthesis with no effect of cell macromolecular synthesis. Also provided are various methods of using this novel protein or the gene encoding this protein.

Abstract: A digital neural network architecture including a forward cascade of layers of neurons, having one input channel and one output channel, for forward processing of data examples that include many data packets. Backward cascade of layers of neurons, having one input channel and one output channel, for backward propagation learning of errors of the processed data examples. Each packet being of a given size. The forward cascade is adapted to be fed, through the input channel, with a succession of data examples and to deliver a succession of partially and fully processed data examples each consisting of a plurality of packets. The fully processed data examples are delivered through the one output channel. Each one of the layers is adapted to receive as input in its input channel a first number of data packets per time unit and to deliver as output in its output channel a second number of data packets per time unit.

Abstract: A method of testing the quality of a fruit including applying a dynamic impact force to the fruit, detecting the mechanical response of the fruit to the dynamic force via a piezoelectric film transducer supported on a displaceable resilient base member such that the film transducer is bent by the dynamic impact force, to induce a strain in the film transducer, and the film transducer outputs an electrical signal corresponding to the change of the induced strain in the film transducer caused by the dynamic force and analyzing the electrical signal to indicate the quality of the fruit. Apparatus for carrying out the method is also described and claimed.

Abstract: A medical anchor device for implantation into a bone of a patient includes a staple having a leading, bone-boring tip for self-tapping a hole, a trailing, driven end for receiving implanting force to self-tap and implant said staple into the bone of a patient, and an attached suture thread. The staple has a longitudinal axis which passes through the tip and the driven end, the longitudinal axis changing shape upon implantation of the staple into a bone. A method of treating a patient includes ejecting and implanting the staple comprising a suture thread secured thereto into a bone by self-tapping a hole in the bone and securing the suture thread to a portion of the body's anatomy.

Abstract: The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a vector with a DNA sequence coding for a cellular injury element promoter from nucleotides -74 to -35 of the GADD153 promoter, relative to the start of transcription. The vector includes an origin of replication in operable linkage with a DNA sequence coding for the promoter. Also, a host cell is transfected with the vector and expresses the cellular injury response element promoter.